TKI + anti-PD-1 antibody-China Medical University, China-colorectal adenocarcinoma

This combination therapy refers to a Phase II clinical trial regimen (NCT04716634) led by China Medical University for patients with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal adenocarcinoma. The study evaluates the efficacy and safety of combining a tyrosine kinase inhibitor (TKI)—specifically either fruquintinib or regorafenib—with the anti-PD-1 monoclonal antibody toripalimab. Fruquintinib is a highly selective inhibitor of VEGFR1, 2, and 3, while regorafenib is a multi-kinase inhibitor targeting VEGFRs, TIE2, PDGFR, FGFR, KIT, RET, and RAF. Toripalimab is a biologic that blocks the PD-1 receptor, facilitating an anti-tumor immune response. This combination is particularly aimed at overcoming the resistance of MSS/pMMR colorectal cancers to standard immunotherapy by leveraging the immunomodulatory effects of anti-angiogenic TKIs to create a more favorable tumor microenvironment.

Brand names

ElunateStivargaTuoyi

Other names

fruquintinib + toripalimabregorafenib + toripalimabTKI + anti-PD-1 antibody